Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Net Cash Flow (2024 - 2025)

Historic Net Cash Flow for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $21.0 million.

  • Prelude Therapeutics' Net Cash Flow rose 22562.0% to $21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year change of. This contributed to the annual value of -$12.8 million for FY2024, which is 14119.31% down from last year.
  • Prelude Therapeutics' Net Cash Flow amounted to $21.0 million in Q3 2025, which was up 22562.0% from -$14.5 million recorded in Q2 2025.
  • Prelude Therapeutics' Net Cash Flow's 5-year high stood at $27.8 million during Q1 2025, with a 5-year trough of -$16.7 million in Q3 2024.